CA4P Is Well Tolerated, May Benefit Platinum-resistant Ovarian Cancer Patients, Trial Shows

CA4P Is Well Tolerated, May Benefit Platinum-resistant Ovarian Cancer Patients, Trial Shows
Data from the second interim analysis of the ongoing Phase 2/3 FOCUS study has shown that Mateon Therapeutics' CA4P (combretastatin a4-phosphate), also known as fosbretabulin, may prolong the time to disease progression or death, when added to the standard of care for platinum-resistant ovarian cancer. "We are encouraged that early data on the primary endpoint of the study continue to favor CA4P and that our investigational drug remains well tolerated," William D. Schwieterman, MD, president and CEO of Mateon, said in a press release. "There is a large unmet medical need in the ovarian cancer market as patients with prOC have low survival rates and few treatment options." CA4P was designed to target blood vessels and the blood supply within tumors. This investigational drug is expected to deprive cancer cells of oxygen and nutrients, triggering their death. The FOCUS trial (NCT02641639) was designed to assess the safety and efficacy of CA4P compared to placebo, when given in combination with Avastin (bevacizumab) and a physician's choice chemotherapy to patients with platinum-resistant ovarian cancer. Eligible patients had received at least one, but no more than two, prior platinum-based regimens. The trial's primary objective was to determine the time to disease progression or death, a measure called progression-free survival (PFS). Other efficacy measures include objective response rate (ORR), overall survival (OS), and overall safety. Conducted in research centers in the United States, Belgium, and Germany, the study has enrolled
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *